<DOC>
	<DOCNO>NCT02266940</DOCNO>
	<brief_summary>This open label , randomise , 3 treatment , 3 period crossover study . This study design assess relative bioavailability DS 1971a tablet formulation reconstitute oral suspension effect high fat meal relative bioavailability DS 1971a tablet formulation .</brief_summary>
	<brief_title>Relative Bioavailability DS-1971a Suspension Tablets Food Effect DS-1971a Tablets</brief_title>
	<detailed_description />
	<criteria>Male female subject age 18 65 year , inclusive Subjects must good general health determine medical history , physical examination screen investigation , take regular medication A body mass index ( BMI ) range 18 30 kg/m^2 , inclusive , weigh 50 100 kg . BMI calculate weight [ kg ] / ( height [ ] ) ^2 Female subject must nonchildbearing potential follow : Must postmenopausal ( last menstrual period least 12 month Screening , follicle stimulate hormone [ FSH ] test Screening confirms postmenopausal status ) ; Must surgically sterile undergone hysterectomy , bilateral oophorectomy , bilateral salpingectomy and/or bilateral tubal ligation Willing able consume standard Food Drug Administration ( FDA ) high fat meal Willing comply study restriction , include use contraception , concomitant medication , dietary lifestyle restriction Sufficient intelligence understand nature study hazard participate . Ability communicate satisfactorily Investigator participate , comply requirement , entire study Have give write consent participate read information consent form , opportunity discus study Investigator his/her delegate Have give write consent his/her data enter The Overvolunteering Prevention System ( TOPS ) Clinically relevant abnormal history , physical finding , ECG finding , laboratory value could interfere objective study safety subject Presence history acute chronic illness , include ( limited ) liver kidney disease , hypertension , seizure , know impairment endocrine , specific bodyorgan dysfunction Presence history severe adverse reaction medicine Presence history malignant disease Acute chronic infectious disease , include human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) C virus ( HCV ) infection Surgery ( eg , stomach bypass ) medical condition might affect absorption medicine Significant illness within 4 week dose study medication Participation another clinical study new chemical entity prescription medicine within previous 3 month , unwilling abstain participate clinical study study 3 month receipt final dose study medication Participation another clinical study DS1971a Blood pressure ( BP ) heart rate semi supine position screen examination outside range 90140 mmHg systolic , 4090 mmHg diastolic ; heart rate 40100 beats/min . Subjects Stage 1 hypertension ( systolic 140 160 mmHg ; diastolic 90 100 mmHg ) may enrol provide evidence end organ damage , diabetes 10 year cardiovascular risk &gt; 20 % Estimated glomerular filtration rate ( eGFR ) &lt; 80 mL/min/1.73m^2 absolute creatinine value upper limit normal ( ULN ) . eGFR estimate Screening use modification diet renal disease ( MDRD ) equation Abnormal ECG waveform morphology Screening would preclude accurate measurement QT interval duration Corrected QT interval ( Fridericia 's formula ) ( QTcF ) interval duration &gt; 430 msec men &gt; 450 msec woman , obtain average measurement duplicate screen ECGs Use prescription medicine overthecounter ( OTC ) medication , herbal remedy ( St John 's Wort ) , food know strong inhibitor strong inducer cytochrome ( CYP ) enzyme ( also know CYP450 enzyme ) 30 day dose study medication ; use prescription OTC medicine , include dietary supplement herbal remedy , 7 day first dose study medication Consumption certain food beverage dose throughout study period Loss 400 mL blood 3 month study , eg , blood donor Abuse drug alcohol 2 year first dose study medication , intake 21 unit alcohol weekly ( men ) 14 unit alcohol weekly ( woman ) Use tobacco product nicotine contain product 3 month dose trial medication Likely possibility volunteer cooperate requirement protocol Objection General Practitioner ( GP ) volunteer enter study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>pharmacokinetics</keyword>
</DOC>